{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-26-000119","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2026-08-11T11:33:42+00:00","discovered_at":"2026-08-11T11:35:00.262574+00:00","generated_at":"2026-08-11T11:35:08.072337+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Autolus Q2 revenue up 119% to $45.7M; FY26 guidance raised to $140-150M","bullets":["Q2 2026 net product revenue $45.7M vs $20.9M YoY (+119%); Q1 2026 was $26.2M.","Gross margin jumped to 55% in Q2 from 6% in Q1 2026 on higher volumes and cost cuts.","Net loss narrowed to $39.1M ($0.15/sh) from $47.9M ($0.18/sh) in Q2 2025.","Closed $75M tranche of up to $250M five-year interest-only Perceptive Advisors credit facility.","Workforce reduction ~13% to save ~$15M annual opex; cash $201.6M at June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-26-000119","json":"https://secwatch.observer/filing/0001730463-26-000119.json","markdown":"https://secwatch.observer/filing/0001730463-26-000119.md","text":"https://secwatch.observer/filing/0001730463-26-000119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000119/0001730463-26-000119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000119/autl-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:35:08.072337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}